ICAM1 and rheumatoid arthritis: To create a bispecific antibody format with therapeutic activity in RA and targeting capacity for the inflamed synovium, the gold standard for anti‐TNF biologic drugs, adalimumab, was coupled with an ICAM‐1–targeting antibody, using an adaptation of the well‐established DVD‐Ig format 17.